Stockhead on MSN18h
Crucible: This rare blood disease tackler plans to hit investors with its best shotThe myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...
Stockhead on MSN13h
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agentBrazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix. ... Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback